Performance on the Latin American version of the Face-Name Associative Memory Exam (LAS-FNAME) distinguishes individuals with Mild Cognitive Impairment from age-matched controls in a sample from Argentina.

INTRODUCTION: The Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) has shown promise in identifying cognitive changes in those at risk for Alzheimer's disease (AD). However, its applicability for Mild Cognitive Impairment (MCI) detection in the Latin American population remains unexplored. This study aims to analyze the psychometric properties in terms of validity and reliability and diagnostic performance of the LAS-FNAME for the detection of memory disorders in patients with amnestic MCI (aMCI). MATERIALS AND METHODS: The study included 31 participants with aMCI, diagnosed by a neurologist according to Petersen's criteria, and 19 healthy controls. Inclusion criteria for the aMCI group were to be 60 years of age or older, report cognitive complaints, have a memory test score (Craft Story 21) below a -1.5 z-score and have preserved functioning in activities of daily living. Participants completed LAS-FNAME and a comprehensive neuropsychological assessment. RESULTS: LAS-FNAME showed the ability to discriminate against healthy controls from patients with aMCI (AUC= 75) in comparison with a gold-standard memory test (AUC = 69.1). LAS-FNAME also showed evidence of concurrent and divergent validity with a standard memory test (RAVLT) (r = 0.58, p < .001) and with an attention task (Digit Span) (r = -0.37, p = .06). Finally, the reliability index was very high (α = 0.88). DISCUSSION: LAS-FNAME effectively distinguished aMCI patients from healthy controls, suggesting its potential for detecting early cognitive changes in Alzheimer's prodromal stages among Spanish speakers.

Síndrome hemolítico urémico asociado a infección por E. coli productor de toxina de shiga / Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome

E.coli productora de Toxina Shiga (STEC), también conocida como E.coli entero- hemorrágica (EHEC), provoca un amplio espectro de manifestaciones clínicas, ya sea en brote o en forma esporádica, que incluyen dolor abdominal, fiebre leve o ausente, con o sin vómitos, diarreas (sanguinolenta o no), y complicaciones extraintestinales como: síndrome hemolítico urémico (SHU) que se observa hasta en un 5-6 por ciento de niños infectados, y púrpura trombocitopénico (7 por ciento de adultos). EI principal factor de virulencia es la producción de una familia de moléculas denominada STX (Shiga toxin), de las cuales STX 1 y 2 son las más frecuentes y característica distintiva de estos E.coli. EI principal serogrupo involucrado en Chile es O157:H7 pero también se han aislado 026, 055, 02, 0117 y 06 (generalmente clasificadas como E. coli serogrupo clásico, no enterohemorrágico). Es fundamental para el clínico conocer la epidemiología, sintomatología y los exámenes que permitan un diagnóstico rápido para manejo terapéutico adecuado, y así evitar las complicaciones enunciadas anteriormente.

Shiga toxin producing E.coli (STEC), also known as enterohemorragic E.coli (EHEC), are responsible for a wide variety of clinical manifestations, both epidemic and sporadic. These include abdominal pain, no fever to mild fever, with or without vomits, diarrhea (bloody or not) and extraintestinal complications, such as haemolytic uremic syndrome in about 5 to 6 percent of children, and trombocitopenic purpura in 1 percent adults. The main virulence factor involved is the production of STX (Shiga toxin). In Chile there is marked prevalence of E.coli serogroup 0157 :H7 in these cases, although it has been associated also to E.coli 026, 055,02,0117 and 06, considered as classic serogroup (not enterohemorragic). It is of outmost importance for clinicians to be aware of symptoms and signs of this disease, as well as diagnostic methods that allow a prompt and adequate treatment, in order to avoid complications.

Infecciones sistémicas por levaduras en un hospital general: correlación entre estudio de susceptibilidad in vitro y supervivencia de los pacientes al episodio de infección fúngica / Systemic yeast infections in a general hospital: correlation between antifungal susceptibility and patient survival

Background: Fungi are important causal agents of nosocomial infections, that usually have high mortality rates. Aim: To evaluate the species distribution and susceptibility patterns of deep yeast infections in a General Hospital and to correlate those results with patient survival. Material and methods: Twenty one strains (from five pediatric and 16 from adult patients) were studied. Antifungal Susceptibility Testing (AST) to Amphotericin B (Anfb), Fluorocytosine (5FC), Fluconazole (FZ) and Itraconazole (IZ) was performed according to the EUCAST document. Clinical data of patients was obtained and survival to the infection was recorded. Results: C. albicans was isolated in 11 samples (52 percent), C. parapsilosis in three samples (14 percent), C. glabrata in two samples (9 percent), C. tropicalis in one sample (5 percent) and C. neoformans in four samples (19 percent). Twenty three percent of fungi were recovered at the Surgical Intensive Care Unit. The MICs ranged between 0.25 and 0.5 µg/mL for Anfb; between 0.25 and 16 µg/ml for SFC, between 0.12 and 32 µg/mL for FZ and 0.015 and 0.5 µg/mL for IZ. No association between antifungal susceptibility and patient survival was observed. Conclusions: C. albicans continues to be the most frequently isolated yeast, however, non-albicans species are an emergent group causing nosocomial infections. Surgical procedures are the main source of fungal infections in this sample